Abstract
Despite great advances in our understanding of the molecular basis of lung cancer, the efficacy of chemotherapy of lung cancer remains disappointingly low (1). Most of the drugs with established activity against lung cancer were developed using mice with transplantable solid tumors of either murine or human origin. In the 1980s, methods were developed for semi-automated testing of drugs against multiple cell lines (2,3). This allowed the feasibility of an alternative, in vitro approach to the discovery of new anticancer drugs to be explored. Thirty cell lines representing eight lung cancer pathologies, together with 76 other cell lines representing other carcinomas, gliomas, leukemias, melanomas, and sarcomas, were collected in a major initiative by the U.S. National Cancer Institute (NCI) (4). Tens of thousands of new drugs have been screened against this panel and multiple relationships linking growth inhibition, resistance mechanisms, and other genetic characteristics have been elucidated (5,6). However, recent studies have also highlighted the differences between cell lines and tumors growing in vivo. In particular, the patterns of gene expression of cell lines in the NCI cell line panel, when measured by microarray analysis, are more like each other than like those of tumors growing in vivo (7).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hoffman, P. C., Mauer, A. M., and Vokes, E. E. (2000) Lung. cancer. Lancet 355, 479ā485.
Finlay, G. J., Baguley, B. C., and Wilson, W. R. (1984) A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal. Biochem. 139, 272ā277.
Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A., Tierney, S., Nofziger, T. H., et al. (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48, 4827ā4833.
Alley, M. C., Scudiero, D. A., Monks, A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., et al. (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48, 589ā601.
Weinstein, J. N., Kohn, K. W., Grever, M. R., Viswanadhan, V. N., Rubinstein, L. V., et al. (1992) Neural computing in cancer drug development-predicting mechanism of action. Science 258, 447ā451.
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nature Genet. 24, 236ā244.
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nature Genet. 24, 227ā235.
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S. J., Mutoh, M., et al. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285ā4300.
Wilson, G. D. and McNally, N. J. (1991) Measurement of cell proliferation using bromodeoxyuridine, in Cell Proliferation in Clinical Diagnosis (Hall, P. A., Levison, D. A., and Wright, N. A., eds.), Springer-Verlag, London, pp. 113ā139.
Steel, G. G. (1977) Basic theory of growing cell populations, in Growth Kinetics of Tumours, 1st ed. (Steel, G. G., ed.), Clarendon, Oxford pp. 56ā85.
Komaki, R., Milas, L., Ro, J. Y., Fujii, T., Perkins, P., Allen, P., et al. (1998) Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer. Int. J. Rad. Oncol. Biol. Phys. 40, 787ā796.
Sirzen, F., Zhivotovsky, B., Nilsson, A., Bergh, J., and Lewensohn, R. (1998) Higher spontaneous apoptotic index in small cell compared with non-small cell lung carcinoma cell lines; lack of correlation with Bcl-2/Bax. Lung Cancer 22, 1ā13.
Baguley, B. C., Marshall, E. S., Whittaker, J. R., Dotchin, M. C., Nixon, J., McCrystal, M. R., et al. (1995) Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. Eur. J. Cancer 31A, 230ā237.
Baguley, B. C., Marshall, E. S., Holdaway, K. M., Rewcastle, G. W., and Denny, W. A. (1998) Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases. Eur. J. Cancer 34, 1086ā1090.
Baguley, B. C., Marshall, E. S., and Finlay, G. J. (1999) Short-term cultures of clinical tumor material: potential contributions to oncology research. Oncol. Res. 11, 115ā124.
Smith, J. A. and Martin, L. (1973) Do cells cycle? Proc. Natl. Acad. Sci. USA 70, 1263ā1267.
Cross, F., Roberts, J., and Weintraub, H. (1989) Simple and complex cell cycles. Annu. Rev. Cell Biol. 5, 341ā395.
Eastman, A. (1990) Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2, 275ā280.
Marshall, E. S., Finlay, G. J., Matthews, J. H. L., Shaw, J. H. F., Nixon, J., and Baguley, B. C. (1992) Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines. J. Natl. Cancer. Inst. 84, 340ā345.
Ludeman, S. M. (1999) The chemistry of the metabolites of cyclophosphamide. Curr. Pharmaceut. Design 5, 627ā643.
Cross, P., Marshall, E. S., Baguley, B. C., Finlay, G. J., Matthews, J. H. L., and Wilson, W. R. (1994) Assessment of proliferative assays for radiosensitivity of 542 Baguley et al. tumor cell lines using high throughput microcultures. Rad. Oncol. Invest. 1, 249ā260.
Marshall, E. S., Matthews, J. H. L., Shaw, J. H. F., Nixon, J., Tumewu, P., Finlay, G. J., et al. (1994) Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]-thymidine incorporation and soft agar clonogenic assays. Eur. J. Cancer 30A, 1370ā1376.
Bridges, A. J. (1996) The epidermal growth factor receptor family of tyrosine kinases and cancer: can an atypical exemplar be a sound therapeutic target? Curr. Med.Chem. 3, 211ā226.
Mendelsohn, J. and Fan, Z. (1997) Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer. Inst. 89, 341ā343.
Bridges, A. J., Zhou, H., Cody, D. R., Rewcastle, G. W., McMichael, A., Showalter, H. D., et al. (1996) Tyrosine kinase inhibitors. 8. An unusually steep structureactivity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 39, 267ā276.
Finlay, G. J. (1992) In vitro systems for anti-cancer drug screening, in The Search for New Anti-Cancer Drugs, 1st ed. (Waring, M. J. and Ponder, B. A., eds.), Kluwer, Dordrecht, pp. 55ā85.
Hamburger, A. W. and Salmon, S. E. (1977) Primary bioassay of human tumor stem cells. Science 197, 461ā463.
Courtenay, V. D., Selby, P. J., Smith, I. E., Mills, J., and Peckham, M. J. (1978) Growth of human tumour cell colonies from biopsies using two soft-agar techniques. Br. J. Cancer 38, 77ā81.
Rubin, R. and Baserga, R. (1995) Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab. Invest. 73, 311ā331.
Kovar, J., Stunz, L. L., Stewart, B. C., Kriegerbeckova, K., Ashman, R. F., and Kemp, J. D. (1997) Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13. Pathobiology 65, 61ā68.
Leist, M., Raab, B., Maurer, S., Rosick, U., and Brigelius-Flohe, R. (1996) Conventional cell culture media do not adequately supply cells with antioxidants and thus facilitate peroxide-induced genotoxicity. Free Radic. Biol. Med. 21, 297ā306.
Brower, M., Carney, D. N., Oie, H. K., Gazdar, A. F., and Minna, J. D. (1986) Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46, 798ā806.
Singletary, S. E., Baker, F. L., Spitzer, G., Tucker, S. L., Tomasovic, B., Brock, W. A., et al. (1987) Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res. 47, 403ā406.
Meredith, J. E., Fazeli, B., and Schwartz, M. A. (1993) The extracellular matrix as a cell survival factor. Mol. Biol. Cell. 4, 953ā961.
Ruoslahti, E. and Reed, J. C. (1994) Anchorage dependence, integrins, and apoptosis. Cell 77, 477ā78.
Frisch, S. M., Vuori, K., Ruoslahti, E., and Chanhui, P. Y. (1996) Control of adhesion-dependent cell survival by focal adhesion kinase. J. Cell. Biol. 134, 793ā799.
Baker, F. L., Spitzer, G., Ajani, J. A., Brock, W. A., Lukeman, J., Pathak, S., et al. (1986) Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium. Cancer Res. 46, 1263ā1274.
Parkins, C. S. and Steel, G. G. (1990) Growth and radiosensitivity testing of human tumour cells using the adhesive tumour cell culture system. Br. J. Cancer 62, 935ā941.
Girinsky, T., Lubin, R., Pignon, J. P., Chavaudra, N., Gazeau, J., Dubray, B., et al. (1993) Predictive value of in vitro radiosensitivity parameters in head and neck cancers and cervical carcinomas: preliminary correlations with local control and overall survival. Int. J. Rad. Oncol. Biol. Phys. 25, 3ā7.
Tanigawa, N., Kitaoka, A., Yamakawa, M., Tanisaka, K., and Kobayashi, H. (1996) In vitro chemosensitivity testing of human tumours by collagen gel droplet culture and image analysis. Anticancer Res. 16, 1925ā1930.
Weisenthal, L. M., Dill, P. L., Kurnick, N. B., and Lippman, M. E. (1983) Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res. 43, 258ā264.
Gazdar, A. F., Steinberg, S. M., Russell, E. K., Linnoila, R. I., Oie, H. K., Ghosh, B. C., et al. (1990) Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J. Natl. Cancer. Inst. 82, 117ā124.
Lefer, A. M. and Lefer, D. J. (1993) Pharmacology of the endothelium in ischemiareperfusion and circulatory shock. Annu. Rev. Pharmacol. Toxicol. 33, 71ā90.
Levine, R. L. (1993) Ischemia-from acidosis to oxidation. FASEB J. 7, 1242ā1246.
Slater, A. F., Stefan, C., Nobel, I., van den Dobbelsteen, D. J., and Orrenius, S. (1995) Signalling mechanisms and oxidative stress in apoptosis. Toxicol. Lett. 82-83, 149ā153.
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer. Inst. 82, 1107ā1112.
Finlay, G. J., Wilson, W. R., and Baguley, B. C. (1986) Comparison of in vitro activity of cytotoxic drugs toward human carcinoma and leukaemia cell lines. Eur. J. Cancer Clin. Oncol. 22, 655ā662.
Sevin, B. U., Peng, Z. L., Perras, J. P., Ganjei, P., Penalver, M., and Averette, H. E. (1988) Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol. Oncol. 31, 191ā204.
Jordan, M. A., Wendell, K., Gardiner, S., Derry, W. B., Copp, H., and Wilson, L. (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56, 816ā825.
Fan, S. J., Eldeiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., et al. (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54, 5824ā5830.
Parmar, J., Marshall, E. S., Charters, G. A., Holdaway, K. M., Shelling, A. N., and Baguley, B. C. (2000) Radiation-induced cell cycle delays and p53 status of early passage melanoma lines. Oncol. Res. 12, 149ā155.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Baguley, B.C., Marshall, E.S., Christmas, T.I. (2003). Cultures of Surgical Material from Lung Cancers. In: Driscoll, B. (eds) Lung Cancer. Methods in Molecular Medicineā¢, vol 74. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-323-2:527
Download citation
DOI: https://doi.org/10.1385/1-59259-323-2:527
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-0-89603-985-8
Online ISBN: 978-1-59259-323-1
eBook Packages: Springer Protocols